IceCure FInancing; U.S. ProSense breast cancer cryoablation install base up 70% on FDA authorization.
IceCure Medical prices $5.5 million private placement at $3.00 per share and issues new Series D and E warrants
- Private placement is with a single healthcare-focused institutional investor participating in the $5.5 million financing round.
- Company agrees to reprice certain March 2026 warrants, subject to shareholder approval of the warrant repricing terms.
- U.S. ProSense breast cancer cryoablation install base rises 70% following FDA marketing authorization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.